The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib

被引：50
作者：
Deadman, Benjamin J. [1 ]
Hopkin, Mark D. [1 ]
Baxendale, Ian R. [2 ]
Ley, Steven V. [1 ]
机构：
[1] Univ Cambridge, Dept Chem, Innovat Technol Ctr, Cambridge CB2 1EW, England
[2] Univ Durham, Dept Chem, Durham DH1 3LE, England
来源：
ORGANIC & BIOMOLECULAR CHEMISTRY | 2013年 / 11卷 / 11期
关键词：
CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITORS; PHENYLAMINO-PYRIMIDINE PAP; CROSS-COUPLING REACTIONS; CHRONIC GRANULOCYTIC-LEUKEMIA; METAL-HALOGEN EXCHANGE; C-ABL; SELECTIVE INHIBITORS; EFFICIENT SYNTHESIS; POSITIVE LEUKEMIAS;
D O I：
10.1039/c2ob27003j
中图分类号：
O62 [有机化学];
学科分类号：
070303 ; 081704 ;
摘要：
Imatinib (1), nilotinib (2) and dasatinib (3) are Bcr-Abl tyrosine kinase inhibitors approved for the treatment of chronic myelogenous leukemia (CML). This review collates information from the journal and patent literature to provide a comprehensive reference source of the different synthetic methods used to prepare the aforementioned active pharmaceutical ingredients (API's).
引用
收藏
页码：1766 / 1800
页数：35
相关论文
共 122 条
[1]   Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate) [J].
Abe, Hiroyuki ;
Kikuchi, Shinichi ;
Hayakawa, Kazuhide ;
Iida, Tetsuya ;
Nagahashi, Noboru ;
Maeda, Katsuya ;
Sakamoto, Johei ;
Matsumoto, Noriaki ;
Miura, Tomoya ;
Matsumura, Koji ;
Seki, Noriyoshi ;
Inaba, Takashi ;
Kawasaki, Hisashi ;
Yamaguchi, Takayuki ;
Kakefuda, Reina ;
Nanayama, Toyomichi ;
Kurachi, Hironori ;
Hori, Yoshikazu ;
Yoshida, Takayuki ;
Kakegawa, Junya ;
Watanabe, Yoshihiro ;
Gilmartin, Aidan G. ;
Richter, Mark C. ;
Moss, Katherine G. ;
Laquerre, Sylvie G. .
ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (04) :320-324
[2]  
Abel S., 2006, [No title captured], Patent No. [WO2006/135640, 2006135640]
[3]  
Aboutaleb E., 2009, INT SEMIN SURG ONCOL, V6
[4]  
Anli H., 2009, IP COM J, Patent No. 7507821
[5]  
[Anonymous], [No title captured], Patent No. 2004005281
[6]  
[Anonymous], [No title captured], Patent No. 2005077945
[7]  
[Anonymous], 2011, US STEMS SEL INT NON
[8]  
[Anonymous], 2009, IP.com Journal, V9, P259, Patent No. 0062778
[9]   A scaleable synthesis of BAY 43-9006: A potent Raf kinase inhibitor for the treatment of cancer [J].
Bankston, D ;
Dumas, J ;
Natero, R ;
Riedl, B ;
Monahan, MK ;
Sibley, R .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2002, 6 (06) :777-781
[10]  
Barrish J. C., 2005, US Pat, Patent No. [20050288303, 20100139979]
12345678910